 
EVALUATION OF THE PHARMACOKINETICS AND 
PHARMACODYNAMICS OF GANCICLOVIR IN PREMATURE 
INFANTS RECEIVING TREATMENT FOR CYTOMEGALOVIRUS 
INFECTION 
DMID Protocol Number: 11-0067 
 
DMID Funding Mechanism:   HHSN272201100037C 
Sponsor:  DMID 
Principal Investigator:  [INVESTIGATOR_10086] W. Kimberlin, M.D.  
DMID Clinical Project Manager:  Walla Dempsey, Ph.D. 
DMID Medical Monitor: Venus Shahamatdar, M.D. 
Version Number:   2.[ADDRESS_553915] 2015  	
	
 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553916] met 
protocol eligibility criteria.  This trial will be conducted in compliance with the protocol, 
International Conference on Harmonization G ood Clinical Practice guidelines (ICH-E6), 
and the applicable regulatory requirements, including: 
 U.S. Code of Federal Regulations applicable  to clinical studies (45 CFR 46 and 21 
CFR including parts 50 and 56 concerning in formed consent and IRB regulations, if 
under IND, 21 CFR 312). 
 Completion of Human Subjects Protection Training.  Refer to 
http://grants.nih.gov/grants/guide /notice-files/NO T-OD-01-061.html ; 
http://cme.cancer.gov/clinicaltrials /learning/humanparticipant-protections.asp   
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553917] 2015 
 
  
 _____________________________________________________________________________________________  
iii SIGNATURE [CONTACT_437252] “ Evaluation of the 
Pharmacokinetics and Pharmacodynamics of Ganciclovir in Premature Infants Receiving Treatm ent for Cytomegalovirus Infection
” 
and attachments  and provides the necessary assurances  that this trial will be conducted 
according to all stipulations of the pr otocol, including all statements regarding 
confidentiality, and according to local l egal and regulatory r equirements and applicable 
U.S. federal regulations and I CH guidelines.  It is understood th at no deviations from the 
protocol may be made without pe rmission of the Sponsor.   
 
Site Investigator: 
 Signed:  Date:  
 Name 
 
   
 [CONTACT_437253] #11-0067, Version 2.[ADDRESS_553918] 2015 
 
  
 _____________________________________________________________________________________________  
iv TABLE OF CONTENTS 
Page 
Statement of Compliance………………………………………………………………………………... ii  
Signature [CONTACT_3490]………………………………… …………………………………………………………iii  
Table of Contents………………………… ……………………………………………………………... iv  
List of Abbreviations……………………………………………………………………………………...vi  
Protocol Summary……………………………………………………………………………………… viii  
1 Key Roles…………………………………………………………………………………………... 1  
2 Background Information and Scientif ic Rationale……………………………………………… 6  
2.1 Background Information ........................................................................................... 6  
2.2 Rationale .................................................................................................................. 7  
2.3 Potential Risks and Benefits ..................................................................................... 7  
2.3.1 Potential Risks .............................................................................................. 7  
2.3.2 Known Potential Benefits .............................................................................. 8  
3 Objectives…………………………………………………………………………………………...9  
3.1 Study Objectives ...................................................................................................... 9  
3.2 Study Outcome Measures ........................................................................................ 9  
3.2.1 Primary Outcome Measures ......................................................................... 9  
3.2.2 Secondary Outcome Measures .................................................................... 9  
3.2.3 Exploratory Outcome Measures ................................................................... 9  
4 Study Design………………………………………………………………………………………10  
5 Study Enrollment and Withdraw al……………………………………………………………… [ADDRESS_553919] Exclusion Criteria ...................................................................................... 12  
5.3 Treatment Assignment Procedures ........................................................................ 12  
5.3.1 Randomization Procedures ........................................................................ 12  
5.3.2 Reasons for Delaying Study-Related Procedures ...................................... 12  
5.3.3 Reasons for Withdrawal ............................................................................. 13  
5.3.4 Handling of Withdrawals ............................................................................. 13  
5.3.5 Termination of Study .................................................................................. 13  
6 Study Intervention/Investigational Product……………………………………………………. 14  
8 Study Procedures/Evaluations…………………………………………………………………..23  
8.1 Clinical Evaluations ................................................................................................ 23  
8.1.1. Baseline Demographics ............................................................................... 23  
8.2 Laboratory Evaluations ........................................................................................... 23  
8.2.1 Special Assays or Procedures .................................................................... 23  
8.2.2 Specimen Preparation, Handling, and Shippi[INVESTIGATOR_007] ......................................... 26  
8.3 PRBC Transfusion Assessment ............................................................................. 27  
9 Assessment of Safety…………………………………………………………………………….28  
9.1 Safety Reporting:  Adverse Events of Special Interest (AESI) ............................... 28  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553920]. ............................ 28  
9.3.2 Discontinuation of Study Enrollment Pending Sponsor Review ................. 29  
9.4 DMID Safety Oversight ........................................................................................... 30  
9.5 FDA MedWatch Adverse Event Reporting Program .............................................. 31  
10 Clinical Monitoring………………………………………………………………………………...32  
10.1 Site Monitoring Plan ............................................................................................... 32  
11 Statistical Considerations……………………………………………………………………….. 33  
11.1 Study Hypotheses .................................................................................................. 33  
11.2 Sample Size Considerations .................................................................................. 33  
11.3 Planned Interim Analyses (if applicable) ................................................................ 34  
11.4 Final Analysis Plan ................................................................................................. 34  
12 Source Documents and Access to Sour ce Data/Documents………………………………...36  
13 Quality Control and Quality A ssurance…………………………………………………………37  
14 Ethics/Protection of Human Subjects…………………………………………………………...[ADDRESS_553921] ...................................................................................... 38  
14.3 Informed Consent Process ..................................................................................... 38  
14.3.1 Informed Consent/Assent Process (in Case of a Minor)............................. 39  
14.4 Exclusion of Women, Minorities, and Children (Special Populations) .................... [ADDRESS_553922] K eepi[INVESTIGATOR_007]…………………………………………………………… 42  
15.1 Data Management Responsibilities ........................................................................ 42  
15.2 Data Capture Methods ........................................................................................... 43  
15.3 Types of Data ......................................................................................................... 43  
15.4 Timing/Reports ....................................................................................................... 43  
15.5 Study Records Retention ....................................................................................... 43  
15.6 Protocol Deviations ................................................................................................ 43  
16 Publication Policy………………………………………………………………………………… 45  
17 Literature References……………………………………………………………………………. 46  
Supplements/Appendices…………………… ………………………………………………………… 49  
Appendix A: Schedule of Events (following Acquisition of Informed Consent)…………………... 50 
  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553923] OF ABBREVIATIONS 
  
  
AE Adverse Event/Adverse Experience 
AESI Adverse Event Special Interest AUC Area Under the Curve 
CASG Collaborative Antiviral Study Group 
CFR Code of Federal Regulations CMV Cytomegalovirus 
CQMP Clinical Quality Management Plan 
CRF Case Report Form CROMS Clinical Research Operations and Management Support 
DAIDS Division of AIDS 
DHHS Department of Health and Human Services DMID Division of Microbiology and Infectious Diseases, NIAID, NIH, 
DHHS 
eCRF Electronic Case Report Form FDA Food and Drug Administration 
FWA Federalwide Assurance 
GCP Good Clinical Practice GI Gastrointestinal 
IB Investigator’s Brochure 
ICF Informed Consent Form ICH International Conference on Harmonisation IEC Independent or Institutional Ethics Committee 
IND Investigational New Drug Application 
IRB Institutional Review Board ISM Independent Safety Monitor 
KG Kilogram 
MG Milligram mL Milliliter 
MOP Manual of Procedures 
NIAID National Institute of Allergy and Infectious Diseases, NIH, DHHS NIH National Institutes of Health 
OHRP Office for Human Research Protections 
PCR Polymerase Chain Reaction PD Pharmacodynamic 
PHI Protected Health Information 
PI [INVESTIGATOR_437215] #11-0067, Version 2.[ADDRESS_553924] 2015 
 
  
 _____________________________________________________________________________________________  
vii PRBC Packed Red Blood Cell 
QA Quality Assurance QC Quality Control 
SAE Serious Adverse Event/Serious Adverse Experience 
SOP Standard Operating Procedure US [LOCATION_002] 
 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553925] 2015 
 
  
 _____________________________________________________________________________________________  
viii PROTOCOL SUMMARY 
 
Title: Evaluation of the Pharmacokinetics and Pharmacodynamics of 
Ganciclovir in Premature Infants Receiving Treatment for 
Cytomegalovirus Infection  
Phase: Not Applicable (clinical sampling study)  
Population: Male and female premature infants < 32 weeks gestation who 
are being treated for medical reasons with intravenous ganciclovir for proven [e.g., culture- or polymerase chain 
reaction (PCR)-confirmed] CMV infections.  Subjects will be 
stratified according to age (gestational and chronologic)  
Sample Size: 32 
Number of Sites: 15 
Study Duration: [ADDRESS_553926] Participation 
Duration: Up to 7 weeks  
Description of Agent or 
Intervention: None. 
This is not an interventional study.  It is a clinical sampling 
study, and ganciclovir will not be administered as part of the 
protocol. 
 
Objectives: 
  
The goals of the study are to determine ganciclovir 
pharmacokinetic and pharmacodynamic parameters in premature infants who receive IV ganciclovir as part of medical 
care to treat CMV infections. 
 Primary: 
 To define the pharmacokinetics of ganciclovir in premature 
(< 32 weeks gestational age at birth) infants 
 
Secondary: 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553927] 2015 
 
  
 _____________________________________________________________________________________________  
ix  To assess changes in quantitative viral DNA in whole blood 
as a function of ganciclovir pharmacokinetics 
 To assess clearance of CMV in urine as a function of 
ganciclovir pharmacokinetics 
 Exploratory: 
 To assess development of neutropenia as a function of 
ganciclovir pharmacokinetics 
 To determine the potential for the development of resistance 
to ganciclovir as a function of pharmacokinetics, dose, age, 
and duration of therapy  
 
 
Outcome Measures  
 
 
Primary Endpoint: 
• Plasma pharmacokinetics parameters for ganciclovir 
AUC12  
Secondary Endpoints: 
• Plasma pharmacokinetics parameters for ganciclovir, 
including maximum serum concentration (Cmax), half-life 
(T1/2), CL, and Vd 
• Correlation of ganciclovir plasma concentrations with 
CMV whole blood viral load 
• Correlation of ganciclovir plasma concentrations with 
clearance of CMV in urine  
Exploratory Endpoints: 
• Correlation of ganciclovir plasma concentrations with 
neutropenia 
• Detection of resistance to ganciclovir 
 
Description of Study 
Design:  
This is an open-label, multi-center, clinical sampling study to 
assess ganciclovir pharmacokinetics and pharmacodynamics  in 
premature infants undergoing antiviral therapy for CMV.  Only those subjects who receive ganciclovir for clinical reasons will 
be enrolled.  The decision to initiate ganciclovir therapy will be 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553928] 2015 
 
  
 _____________________________________________________________________________________________  
x made by [CONTACT_437230]/her clinical 
decision to treat virologically-confirmed CMV infection; infants receiving such therapy and meeting entry criteria will then be 
eligible for this study.  Therefore, ganciclovir will not be provided 
under this protocol.  
Subjects meeting enrollment criteria will be entered into this 
clinical trial.  Following enrollment, subjects will be stratified by [CONTACT_437231]:  1) ≤ 27 
weeks 6 days gestational age at birth and ≤ 30 days chronologic 
age at study enrollment; 2) ≤ 27 weeks 6 days gestational age 
at birth and > 30 days chronologic age at study enrollment; 3) ≥ 
28 weeks 0 days gestational age at birth and ≤ 30 days 
chronologic age at study enrollment; 4) ≥ 28 weeks 0 days 
gestational age at birth and > 30 days chronologic age at study 
enrollment.  The total sample size across these four cohorts is 32 subjects.  Subjects in each cohort with inadequate pharmacokinetic data for analysis (e.g., due to droppi[INVESTIGATOR_437216], or blood 
sampling obtained but is inadequate for analysis) may be 
replaced and will not count toward the total of [ADDRESS_553929] is receiving intravenous ganciclovir 
therapy.  These specimens will be used to determine viral load 
and ganciclovir resistance.  Since ganciclovir is a renally 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553930] 2015 
 
  
 _____________________________________________________________________________________________  
xi excreted drug, serum creatinine will be drawn for the research 
protocol on the day that the ganciclovir pharmacokinetic specimens are obtained in order to calculate creatinine 
clearance using a method such as the modified Schwartz 
formula, and thus correlate ganciclovir clearance with renal function. Otherwise, data from hematology assessments (WBC 
count and differential, hemoglobin, platelet count) and from 
chemistry labs (serum creatinine, AST, and ALT) will be recorded on the study case report forms during each study 
period if they are being obtained for clinical reasons, but will not 
be drawn only for the purposes of the study.  Ganciclovir dosing information (mg/dose, dosing inte rval, and subject weight) will 
be recorded on the day of the pharmacokinetic blood draws, and 
weekly from Period [ADDRESS_553931] continues to receive intravenous ganciclovir from 
Study Assessment Day 18 through Study Assessment  Day 24 (Period 4), a second PK assessment may be performed at the request of the treating physician if the subject weighs 575  
grams or more at the time of specimen collection. 
Estimated Time to 
Complete Enrollment: [ADDRESS_553932] 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553933] 2015 
 
  
 _____________________________________________________________________________________________  
xii *Schematic of Study Design : 
 
 P A 
R 
E 
N 
T 
E 
R 
A 
L 
 
G 
A 
N 
C 
I 
C 
L 
O 
V 
I 
R 
 
A 
D 
M 
I 
N 
I 
S 
T 
R 
A 
T 
I 
O 
N Period 1 (Study Assessment Day 1 through Study 
Assessment Day 3)  Ganciclovir PK 
Virologic specimens (once per study period) Safety laboratory tests 
Period 2 (Study Assessment Day 4 through Study 
Assessment Day 10) Virologic specimens (once per study period) 
Safety laboratory tests 
Period 3 (Study Assessment Day 11 through Study 
Assessment Day 17) 
Virologic specimens (once per study period) 
Safety laboratory tests 
Period 4 (Study Assessment Day 18 through Study Assessment Day 24)  Ganciclovir PK (if requested by [CONTACT_437232]’s weight is ≥ to 575 grams on the day 
obtained) Virologic specimens (once per study period) 
Safet
y laborator y tests
Period 5 (Study Assessment Day 25 through Study 
Assessment Day 31)  
Virologic specimens (once per study period) 
Safety laboratory tests 
Period 6 (Study Assessment Day 32 through Study Assessment Day 38)  
Virologic specimens (once per study period if 
subject’s weight is ≥ 600 grams on the day obtained) 
Safety laboratory tests 
Period 7 (Study Assessment Day 39 through Study Assessment Day 42)  Virologic specimens (once per study period if 
subject’s weight is ≥ 650 grams on the day obtained) 
Safety laboratory tests 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553934] 2015 
 
  
1 1 KEY ROLES 
Individuals: DMID Clinical Project  Manager : 
Walla Dempsey, PhD 
Virology Branch  Division of Microbiology and Infectious Diseases, NIAID, NIH  
[ADDRESS_553935], MSC 6603  
Bethesda, MD  [ZIP_CODE] (Zip for express mail is [ZIP_CODE]) Phone: [PHONE_3719] Fax: [PHONE_3720] 
[EMAIL_2259]   
 Principal Investigator: 
[INVESTIGATOR_10086] W. Kimberlin, M.D. 
Protocol Chair 
Co-Principal Investigator, Collaborative Antiviral Study Group 
Professor of Pediatrics Sergio Stagno Endowed Chair in Pediatric Infectious Diseases 
The University of Alabama at Birmingham 
[ADDRESS_553936] South, CHB 303 Birmingham, AL  [ZIP_CODE] 
Phone: [PHONE_2597] 
Fax: [PHONE_2599] e-mail: [EMAIL_2260]   
 Program Director: 
Penny Jester BSN MPH CCRC 
Collaborative Antiviral Study Group The University of Alabama at Birmingham 
[ADDRESS_553937] South, CHB 303 
Birmingham, AL  [ZIP_CODE] Phone: [PHONE_2597] 
Fax:  [PHONE_3721] 
e-mail: [EMAIL_2261]   
Clinical Studies Administrator 
Bari Cotton, RN 
Collaborative Antiviral Study Group The University of Alabama at Birmingham [ADDRESS_553938] South, CHB 303 Birmingham, AL  [ZIP_CODE] 
Phone: [PHONE_2597] 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553939] 2015 
 
  
2 Fax: [PHONE_3721] 
e-mail: [EMAIL_8336]    
Medical Monitor:   
Venus Shahamatdar, M.D. Office of Clinical Research Affairs 
Division of Microbiology and Infectious Diseases, NIAID, NIH  
[ADDRESS_553940], 7E54, 
Bethesda, MD  [ZIP_CODE] 
Phone: [PHONE_2600]   Email: [EMAIL_2262]    
Institutions:  
University of Alabama at Birmingham  David W. Kimberlin, M.D.  Department of Pediatrics, Division of Infectious Diseases  [ADDRESS_553941] South, CHB 303  Birmingham, AL [ZIP_CODE]  
Phone: [PHONE_2597]  
Fax: [PHONE_2599]  Email: [EMAIL_2263]   
 
Carolinas Medical Center - Charlotte  
Amina Ahmed, M.D. B.S.  
Department of Pediatrics  [ADDRESS_553942] MEB-4th  Charlotte, NC [ZIP_CODE]  Phone: [PHONE_2601]  Fax:  [PHONE_9091] 
Email: [EMAIL_2265]   
 
Children's Hospi[INVESTIGATOR_437217] G. Michaels, M.D., M.P.H. One Children's Hospi[INVESTIGATOR_289938]  
[ADDRESS_553943] Floor  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  Phone: [PHONE_9092]/[PHONE_9093]  Fax: [PHONE_9094]  Email: [EMAIL_5243]   
 
Children's National Medical Center  
Roberta L. DeBiasi, MD  [ADDRESS_553944] Wing 3.5  Washington, DC [ZIP_CODE]  
Phone: [PHONE_2607]  
Fax: [PHONE_9095]  Email: [EMAIL_2270]  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553945]  
Room 3153  
Baltimore, MD [ZIP_CODE]  Phone: [PHONE_2603]  Fax: [PHONE_104]  Email: [EMAIL_2267]   
 
Louisiana State University Health Science Center – Shreveport John Vanchiere, MD, PhD [ADDRESS_553946]-303 Shreveport, LA  [ZIP_CODE] 
Phone: [PHONE_9096]  
Fax: [PHONE_9097]  Email: [EMAIL_8337]  
 
MetroHealth Medical Center Nazha F. Abughali, M.D.  
Department of Pediatrics 
[ADDRESS_553947] Old Research Bldg  Rm 350 Cleveland, OH [ZIP_CODE] Phone: [PHONE_9098] 
Fax: [PHONE_9099] 
Email: [EMAIL_8338]   
 
Rhode Island Hospi[INVESTIGATOR_437218], MD  Division of Pediatric Infectious Diseases  
[ADDRESS_553948]      
PO Box RM 018  Providence, RI [ZIP_CODE]  Phone: [PHONE_2608]  Fax: [PHONE_9100]  
Email: [EMAIL_2271]   
 
Steven & Alexandra Cohen Children’s Medical Center of [LOCATION_001] (CCMC) Sunil Sood, MD  [ADDRESS_553949]  
9 Tower North Shore University Hospi[INVESTIGATOR_307], Room 8   
Manhasset, NY [ZIP_CODE]  Phone: [PHONE_2613]  Fax: [PHONE_9101]  Email: [EMAIL_2278]   
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553950] 2015 
 
  
4  
University of Arkansas for Medical Sciences  Jose Romero, MD  Arkansas Children's Hospi[INVESTIGATOR_307]  [ADDRESS_553951]  
Pediatric Infectious Diseases, Slot 512-11  
Little Rock, AR [ZIP_CODE]  Phone: [PHONE_9102]  Fax: [PHONE_9103]  Email: [EMAIL_8339]   
 
University of [COMPANY_002]ster Medical Center  Mary Caserta, M.D.  [ADDRESS_553952]  Box 690   
[COMPANY_002]ster, NY [ZIP_CODE]  
Phone: [PHONE_2604]  Fax: [PHONE_6770]  Email: [EMAIL_2268]   
 
University of South [LOCATION_012] School of Medicine 
Jorge Lujan-Zilbermann, MD 
[ADDRESS_553953] Division of Infectious Disease Tampa, [LOCATION_012] [ZIP_CODE]  Phone: [PHONE_2995]  
Fax: [PHONE_9104]  
Email: [EMAIL_8340]  
 
University of [LOCATION_007] – Southwestern Pablo Sanchez, MD  Southwestern Med. Center  
Department of Pediatrics  
[ADDRESS_553954], Rm # E3.508  Dallas, TX [ZIP_CODE]  Phone: [PHONE_9105]  Fax: [PHONE_9106]  
Email: [EMAIL_8341]   
 
Vanderbilt University Medical Center  Natasha B. Halasa, MD, MPH  Pediatric Infectious Diseases  [ADDRESS_553955] South  
D-7235 MCN  
Nashville, TN [ZIP_CODE]  Phone: [PHONE_6775]  Fax: [PHONE_4775]  Email: [EMAIL_8342]   
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553956]. Louis Children's Hospi[INVESTIGATOR_307]  [ADDRESS_553957]. Louis, MO [ZIP_CODE]  Phone: [PHONE_2614]  Fax: [PHONE_9107]  Email: [EMAIL_2279]   
Optional:  
Statistician:  
Inmaculada "Chichi" Aban, PhD Associate [CONTACT_78052] of Biostatistics School of Public Health The University of Alabama at Birmingham 
RPHB 327 
Phone: ([PHONE_2616] Fax: ([PHONE_2617] 
e-mail: [EMAIL_3424]  
 
UAB Antiviral Pharmacology Laboratory: 
Edward P. Acosta, Pharm.D. 
Professor and Director, Division of Clinical Pharmacology University of Alabama at Birmingham 
School of Medicine 
[ADDRESS_553958], Volker Hall, Room 258 Birmingham, AL [ZIP_CODE]
 
Phone: [PHONE_9108] Fax:      [PHONE_9109] e-mail:  [EMAIL_935]  
  
 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553959] that symptomatic disease in preterm babies is less common than asymptomatic infection, and long-term sequelae are rare.
15-19  Nevertheless, 
severe disseminated CMV disease can occur in premature infants, including life-threatening 
pneumonitis, hepatitis, and thrombocytopenia.20  Antiviral therapy in such patients is frequently 
used, albeit without either controlled data to demonstrate benefit or knowledge of proper dosing regimens.
12  In patients with symptomatic congenital CMV disease, six weeks of intravenous 
ganciclovir improves hearing outcomes in early childhood,21 and may benefit 
neurodevelopmental outcomes as well.22  In premature babies with visceral disease from 
postnatally acquired CMV, the goal of antiviral ther apy is different; namely, it is to treat the end-
organ disease, which is occurring at that time, rather than to prevent or improve long-term 
sequelae.  Without efficacy data, the duration of treatment is variable, but anecdotal experience suggests that it generally is in the range of two to four weeks of total antiviral therapy.  
Approximately two-thirds of treated neonates re ceiving six weeks of intravenous ganciclovir 
develop Grade 3 or 4 neutropenia (utilizing the DAIDS Toxicity Tables) during therapy.
[ADDRESS_553960] indicated that the area-under-the-concentration curve (AUC) of ganciclovir is most closely related to virologic treatment success.
23  Data from an 
National Institute of Allergy and Infectious Diseases (NIAID) CASG Phase II study of 
intravenous ganciclovir (6 mg/kg/dose q 12 hrs) in term neonates with symptomatic congenital CMV disease revealed a median AUC
12 of 27 μgxh/mL (mean AUC 12=32.3+13.7 μgxh/mL, 
range 17.2 to 55.9 μgxh/mL, n=13).24  A more recent CASG investigation of oral valganciclovir 
included comparative pharmacokinetic data following 6 mg/kg/dose every 12 hrs of intravenous ganciclovir.  The mean AUC
12 in young neonates (median age: 16.5 days) on the second day 
following study enrollment was 38.2 μgxh/mL (median: 25.5 μgxh/mL), but the coefficient of 
variation was large (112).[ADDRESS_553961] risk for CMV disease 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553962] month of life.21,22,25,27-30  In this study, this experience will be utilized to 
further define the utility of this drug in very premature children.   
2.2 Rationale 
Parenteral ganciclovir is used regularly in premature neonates to treat end-organ disease, but 
the appropriate dose to use has never been studied or defined.  This is a clinical sampling 
study, and premature infants who receive intravenous  ganciclovir as part of clinical care will be 
eligible for participation.  A prospective treatment trial is not feasible at this time, but this study 
will inform dosing parameters for a subsequent  prospective study to evaluate dose and 
effectiveness.  At the completion of the study, appropriate dosing of intravenous ganciclovir in premature infants will be defined.  While this will not allow for conclusions to be drawn regarding 
efficacy, these data will help minimize toxicity for future premature babies treated with 
ganciclovir.  Importantly, all pharmacokinetic assays will be performed in the UAB Antiviral Pharmacology Laboratory.  Of relevance to this trial, this laboratory has developed the 
methodology to process microspecimens of blood for ganciclovir drug concentrations.  
2.3 Potential Risks and Benefits 
2.3.1 Potential Risks 
As a sampling study, the potential risks relate to blood draws (e.g., bruising at the site, infection, 
anemia possibly requiring packed red blood cell transfusion).  Requiring a baby [CONTACT_437233] 
[ADDRESS_553963] long-term 
intravenous access for clinical care, through which blood can be withdrawn without risk of 
discomfort  from the needle stick or bruising at the site during or after the blood drawing and 
rarely an infection.  Transfusions are expected in hospi[INVESTIGATOR_437219].  One study 
reported that extremely premature neonates receiv e an average of 5.2 ± 4.[ADDRESS_553964] of this study, transfusion rates will be carefully monitored.  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553965]’s pharmacokinetic profile may allow for rational clinical 
adjustments in treatment dose, thereby [CONTACT_437234].  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553966] 2015 
 
  
9 3 OBJECTIVES 
3.1 Study Objectives 
Primary: 
 To define the pharmacokinetics of ganciclovir in premature (< 32 weeks gestational age at 
birth) infants 
Secondary: 
 To assess changes in quantitative viral DNA in whole blood as a function of ganciclovir 
pharmacokinetics 
 To assess clearance of CMV in urine as a function of ganciclovir pharmacokinetics 
Exploratory: 
 To assess development of neutropenia as a function of ganciclovir pharmacokinetics 
 To determine the potential for the development of resistance to ganciclovir as a function of 
pharmacokinetics, dose, age, and duration of therapy 
3.2 Study Outcome Measures 
3.2.1 Primary Outcome Measures 
Primary Endpoint: 
Primary Endpoint: 
 
• Plasma pharmacokinetics parameters for ganciclovir AUC12  
3.2.2 Secondary Outcome Measures 
Secondary Endpoints: 
• Plasma pharmacokinetics parameters for ganciclovir, including maximum serum 
concentration (Cmax), half-life (T1/2), CL, and Vd 
• Correlation of ganciclovir plasma concent rations with CMV whole blood viral load 
• Correlation of ganciclovir plasma concentrations with clearance of CMV in urine  
3.2.3 Exploratory Outcome Measures 
Exploratory Endpoints: 
• Correlation of ganciclovir plasma concentrations with neutropenia 
• Detection of resistance to ganciclovir 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553967] 2015 
 
  
10 4 STUDY DESIGN 
This is an open-label, multi-center, clinical sampling study of ganciclovir pharmacokinetics and 
pharmacodynamics of ganciclovir in premature infants undergoing antiviral therapy for CMV.  
Only those subjects who receive ganciclovir for clinical reasons will be enrolled.  The decision to 
initiate ganciclovir therapy will be made by [CONTACT_437230]/her clinical 
decision to treat virologically-confirmed CMV infection; infants receiving such therapy and meeting entry criteria will then be eligible for this study.  Therefore, ganciclovir will be dispensed 
from the institution’s pharmacy and not provided under this protocol. 
 Subjects meeting enrollment criteria will be entered into this clinical trial.  Following enrollment, 
subjects will be stratified by [CONTACT_437231]:  1) ≤ 27 weeks 6 
days gestational age at birth and ≤ 30 days chronologic age at study enrollment; 2) ≤ 27 weeks 
6 days gestational age at birth and > 30 days chronologic age at study enrollment; 3) ≥ 28 
weeks 0 days gestational age at birth and ≤ 30 days chronologic age at study enrollment; 4) ≥ 
28 weeks 0 days gestational age at birth and > 30 days chronologic age at study enrollment.  
The total sample size across these four cohorts is 32 subjects.  Subjects in each cohort with 
inadequate pharmacokinetic data for analysis (e.g., due to droppi[INVESTIGATOR_437220], or blood sampling obtained but is inadequate for analysis) may be 
replaced and will not count toward the total of [ADDRESS_553968] receives 
following enrollment on the trial, and Study Assessment  Day 1 is the calendar day when 
Study Assessment Dose 1 is administered.   Both Treatment Day 1 and Treatment Dose 1 
can coincide with or precede study enrollmen t; Study Assessment Day 1 and Study Assessment 
Dose 1 by [CONTACT_437235], and may or may not equate with Treatment 
Day 1 and Treatment Dose 1.  Typi[INVESTIGATOR_897], ganciclo vir is administered twice per day in these 
infants.  
With the receipt of one of the Study Assessment Doses (dose 3, 4, 5, 6, 7, or 8) of intravenous 
ganciclovir, pharmacokinetic specimens will be obtained at 0h (immediately prior to IV ganciclovir dose; window: -15 min), 1h (immediately after the end of the IV ganciclovir dose; window: +15 min), 2-3h, 5-7h, and 10-12h.  This complete set of pharmacokinetic time points 
will allow for the AUC and clearance (CL) to be calculated in each subject.  Specimens will be 
shipped to the UAB Antiviral Pharmacology Laboratory for processing at that time.  The pharmacokinetic data will then be provided to the study site, including the AUC and CL values, 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553969] the dose will be a clinical one 
to be decided by [CONTACT_1963], and will no t be dictated by [CONTACT_316923].  The 
parameters for AUC and CL from prior CASG ganciclovir27,30 and valganciclovir25,29 studies 
demonstrate that these PK parameters may be useful in guiding dose adjustments.  Duration 
and dose of intravenous ganciclovir therapy is made at the discretion of the treating physician and will not be dictated by [CONTACT_316923].   
 
Both whole blood for CMV PCR and urine for CM V assessment will be obtained serially through 
Study Assessment Period 7 as long as the subjec t is receiving intravenous ganciclovir therapy 
(that is, until the ganciclovir is permanently discontinued).  These specimens will be used to 
determine viral load and, as indicated, ganciclovir resistance.  At each sample collection time, urine will be split into two aliquots.  These aliquots will be available for CMV detection as 
appropriate, based upon whole blood viral loads.  Specimens will then be available for 
subsequent testing for ganciclovir resistance in the UAB Virology Resistance Laboratory.  Since ganciclovir is a renally excreted drug, serum creatinine will be drawn for the research protocol 
on the day that the ganciclovir pharmacokinetic specimens are obtained in order to calculate 
creatinine clearance using a method such as the modified Schwartz formula, and thus correlate ganciclovir clearance with renal function.  Otherwise, data from hematology assessments (WBC count and differential, hemoglobin, platelet count ) and from chemistry labs (serum creatinine, 
ALT, and AST) will be recorded on the study case report forms each study assessment period if 
they are being obtained for clinical reasons, but will not be drawn only for the purposes of the study.  Ganciclovir dosing information (mg/dos e, dosing interval, and subject weight) will be 
recorded on the day of the pharmacokinetic blood draws.  Once a subject is successfully 
enrolled into the study the ganciclovir dosing information (mg/dose and dosing interval) will be recorded from the start of clinical treatment of ganciclovir until date of enrollment.  After 
enrollment ganciclovir dosing information (mg/ dose and dosing interval) will be captured from 
Study Assessment Period 1 through the Study Asse ssment Period 7; as long as the subject is 
receiving intravenous ganciclovir therapy. 
 
If the subject continues to receive intravenous ganciclovir from Study Assessment Day 18 through Study Assessment Day 24 (Period 4), and at the request of the treating physician, an 
additional set of blood samples will be obtained for PK assessments if the subject is [ADDRESS_553970] pharmacokinetic draws. 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553971] 2015 
 
  
12 5 STUDY ENROLLMENT AND WITHDRAWAL 
Male and female premature infants < 32 weeks gestation of any ethnicity who are being treated 
with intravenous ganciclovir for proven [e.g., culture- or polymerase chain reaction (PCR)-confirmed] CMV infections are eligible for enrollment.   Participating clinical sites will identify 
potential study subjects.  Patients meeting study eligibility criteria may be offered enrollment into 
the trial.  Informed consent signed by [CONTACT_62444]’s parent(s) or guardian(s) must be obtained prior to study enrollment.  Site investigators are all clinicians and also care providers for the 
neonatologists at their respective institutions, and therefore have direct access to the study 
population.  The study population will be drawn from the in-hospi[INVESTIGATOR_6885].  Potential subjects will be identified by [CONTACT_437236].  
5.[ADDRESS_553972] Inclusion Criteria 
1. Signed informed consent from parent(s) or legal guardian(s) 
2. Confirmation of CMV infection from urine, blood,  or saliva by [CONTACT_921], shell vial, or PCR tests 
(local lab) 
3. Receiving intravenous ganciclovir, prescribed by [CONTACT_102]’s physician and anticipated to 
receive at least 3 more doses after consenting 
4. < 32 weeks gestational age at birth 5. ≥ [ADDRESS_553973] milk from a mother who is  being treated with ganciclovir or valganciclovir 
4. Current receipt of other investigational drugs 5. Major congenital anomaly that in the site investigator’s opi[INVESTIGATOR_258890]’s volume of distribution 
5.[ADDRESS_553974] risk [e.g., at risk of a packed red blood cell (PRBC) 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553975] 2015 
 
  
13 transfusion due to the removal of blood for the study; however, if the subject would receive a 
transfusion of packed red blood cells even if the study-related labs were not obtained, then this would not be considered a situation of increasing subject risk].  Additionally, a study-related 
laboratory specimen that is unevaluable due to clotting or laboratory related issues will not be 
repeated.  If a study related laboratory draw is  delayed or deferred, study staff will document 
this on a source document.
 
5.3.3 Reasons for Withdrawal 
The criteria for discontinuations during the study include:  
 Study subject (parent/legal guardian) wishes to withdraw 
 Non-compliance with study procedures 
 Trial termination (by [CONTACT_86736], , FDA, DMID, NIAID, NIH, or agreement of all investigators) 
 Any other reason which, in the opi[INVESTIGATOR_871], precludes the study subject's 
participation in the study.  The principal investigator [INVESTIGATOR_437221] a study subject for this reason. 
5.3.[ADDRESS_553976] may be replaced (see Section 4).  
5.3.[ADDRESS_553977] the right to terminate this study at any time.  Reasons for 
terminating the study may include, but are not limited to, the following: 
 Study subject enrollment is unsatisfactory 
 Data recording is inaccurate or incomplete 
 Investigators do not adhere to the protocol or applicable regulatory guidelines in conducting 
the study. 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553978] 2015 
 
  
14 6 STUDY INTERVENTION/INVESTIGATIONAL PRODUCT 
None. 
This is a sampling study with no therapeutic intervention.  Only subjects who receive 
intravenous ganciclovir as practice of medicine will be eligible to enroll.  Intravenous ganciclovir 
will not be provided under this protocol.  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553979]’s parent(s) 
or guardian(s) must be obtained prior to study enrollment.  
7.2 Enrollment/Baseline 
7.2.1.  Baseline Assessment (Period 1:   Study Assessment Day 1 through 
Study Assessment Day 3, unles s broader window specified) 
 Confirm that informed consent has been obtained from parent or legally authorized 
representative 
 Document baseline demographics (see Section 8.1.1; Window: Birth through Study 
Assessment Day 3) 
o Gestational age at delivery 
o Date of birth 
o Day of life at initiation of IV ganciclovir therapy 
o Gender 
o Race 
o Ethnicity 
o Birth weight 
o Weight at enrollment 
o Length in centimeters at enrollment 
o Reason ganciclovir being administered 
o Ganciclovir dose and dosing frequency 
o Manufacturer of the ganciclovir lot utilized at the treating facility 
o Date ganciclovir therapy was initiated 
 Hematology labs (see Section 8.2; Window: Birth through Study Assessment Day 3) 
o WBC with differential, hemoglobin, and platelet count, if being drawn for clinical 
reasons; any laboratory value obtained during the window will suffice, with an effort being made to capture the most abnormal value 
 Chemistry labs (see Section 8.2; Window: Birth through Study Assessment Day 3) 
o AST and ALT, if being drawn for clinical reasons; any laboratory value obtained 
during the window will suffice, with an effort being made to capture the most 
abnormal value 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553980] 2015 
 
  
16  Serum Creatinine (see Section 8.2) 
o To be drawn on the calendar day that ganciclovir PKs are being drawn (Window: 
Study Assessment Day 1 through Study Assessment Day 5)  
o Required amount of whole blood for serum creatinine is 0.25 mL 
 
 Ganciclovir pharmacokinetics (see Section [IP_ADDRESS].) 
o Ganciclovir concentrations will be obtained with one of the Study Assessment 
Dose 3, 4, 5, 6, 7, or 8 (Window:Study Assessment Day 1 through Study 
Assessment Day 5) 
o Timepoints for pharmacokinetic draws:  0h (immediately prior to IV ganciclovir 
dose; window: -15 min), 1h (immediately after the end of the IV ganciclovir dose; window: +15 min), 2-3h, 5-7h, and 10-12h 
o Required amount of whole blood for plasma ganciclovir determination at each 
timepoint is 200 L (0.2 mL) 
 Virology specimens (see Sections [IP_ADDRESS].) 
o Blood for CMV quantitative PCR will be obtained (required amount of whole 
blood for CMV PCR is 0.5 mL) 
o If obtainable, urine for CMV detection will be collected non-invasively (e.g., 
bagged, from indwelling foley catheter, excess clinical specimen, etc.) 
 Clinical treatment ganciclovir dosing information 
o mg/dose 
o Dosing interval 
o Patient weight 
 PRBC transfusion documentation on eCRF 
 Study Assessment ganciclovir dosing information 
o mg/dose 
o Dosing interval 
o Subject weight 
7.3 Follow-up  
7.3.1.  Period 2 (Study  Assessment Day 4 thr ough Study Assessment Day 
10)  
Documentation of receipt of PRBC transfusion(s) will be provided on an eCRF.  If the 
study subject has NOT received ≥ 10 PRBC transfusions (see Section 9.3.1), proceed 
with required assessments. 
Required assessments [following confirmation that subject is still receiving ganciclovir 
(e.g., that the ganciclovir has not been permanently discontinued)]:  1) virology blood 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553981] 2015 
 
  
17 specimens for CMV viral load (required amount of whole blood for CMV PCR is 0.5 mL); 
2) CMV detection from noninvasive urine spec imen (if obtainable); 3) ganciclovir dosing 
information (mg/dose, dosing interval, subject weight). 
Optional assessments (if being drawn for clinical reasons; any laboratory value obtained 
during the window will suffice, with an effort being made to capture the most abnormal value):  1) hematology labs (WBC with differential, hemoglobin, platelet count); 2) 
chemistry labs (AST, ALT); 3) serum creatinine. 
 
Study Assessments (as described) Optional Assessments* 
Virology blood specimens for CMV viral load Hematology labs (WBC with 
differential, hemoglobin, platelet 
count) 
If obtainable, CMV detection from noninvasive urine 
specimen (e.g., bagged, from indwelling foley catheter, excess clinical specimen, etc.) Chemistry labs (AST, ALT) 
Ganciclovir dosing information (mg/dose, dosing 
interval, subject weight) Serum creatinine 
* If being drawn for clinical reasons; any laboratory value obtained during the window will 
suffice, with an effort being made to capture the most abnormal value 
7.3.2.  Period 3 (Study  Assessment Day 11 thr ough Study Assessment Day 
17)  
Documentation of receipt of PRBC transfusion(s) will be provided on an eCRF.  If the 
study subject has NOT received ≥ 10 PRBC transfusions (see Section 9.3.1), proceed 
with required assessments. 
Required assessments [following confirmation that subject is still receiving ganciclovir 
(e.g., that the ganciclovir has not been permanently discontinued)]:  1) virology blood 
specimens for CMV viral load (required amount of whole blood for CMV PCR is 0.5 mL); 
2) CMV detection from noninvasive urine spec imen (if obtainable); 3) ganciclovir dosing 
information (mg/dose, dosing interval, subject weight). 
Optional assessments (if being drawn for clinical reasons; any laboratory value obtained 
during the window will suffice, with an effort being made to capture the most abnormal 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553982] 2015 
 
  
18 value):  1) hematology labs (WBC with differential, hemoglobin, platelet count); 2) 
chemistry labs (AST, ALT); 3) serum creatinine. 
 
Study Assessments (as described) Optional Assessments* 
Virology blood specimens for CMV viral load Hematology labs (WBC with 
differential, hemoglobin, platelet 
count) 
If obtainable, CMV detection from noninvasive urine specimen (e.g., bagged, from indwelling foley 
catheter, excess clinical specimen, etc.) Chemistry labs (AST, ALT) 
Ganciclovir dosing information (mg/dose, dosing 
interval, subject weight) Serum creatinine 
* If being drawn for clinical reasons; any laboratory value obtained during the window will 
suffice, with an effort being made to capture the most abnormal value 
7.3.3.  Period 4 (Study  Assessment Day 18 thr ough Study Assessment Day 
24)  
 Documentation of receipt of PRBC transfusion(s) will be provided on an eCRF.  If the 
study subject has NOT received ≥ 10 PRBC transfusions (see Section 9.3.1), 
proceed with required assessments. 
 Confirmation that subject is still receiving ganciclovir (e.g., that the ganciclovir has 
not been permanently discontinued) 
 Hematology labs (see Section 8.2) 
o WBC with differential, hemoglobin, and platelet count, if being drawn for clinical 
reasons; any laboratory value obtained during the window will suffice, with an 
effort being made to capture the most abnormal value 
 Chemistry labs (see Section 8.2) 
o AST and ALT, if being drawn for clinical reasons; any laboratory value obtained 
during the window will suffice, with an effort being made to capture the most abnormal value 
 Serum creatinine (see Section 8.2) 
o Obtain if the ganciclovir pharmacokinetics are being obtained during this study 
assessment period 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553983] 2015 
 
  
19 o To be drawn on the calendar day that ganciclovir PKs are being drawn 
 Ganciclovir pharmacokinetics, if desired by [CONTACT_437237] ≥ 575 grams at that time (see Section [IP_ADDRESS].) 
o Ganciclovir concentrations may be obtained around one dose in this assessment 
window (Study Assessment Day 18 through Study Assessment Day 24) 
o Timepoints for pharmacokinetic draws:  0h (immediately prior to IV ganciclovir 
dose; window: -15 min), 1h (immediately after the end of the IV ganciclovir dose; window: +15 min), 2-3h, 5-7h, and 10-12h 
o Required amount of whole blood for plasma ganciclovir determination at each 
timepoint is 200 L (0.2 mL) 
o If subject weighs < 575 grams, the second set of PK draws cannot be performed 
 Virology specimens (see Sections [IP_ADDRESS].) 
o Blood for CMV quantitative PCR will be obtained (required amount of whole 
blood for CMV PCR is 0.5 mL) 
o If obtainable, urine for CMV detection will be obtained non-invasively (e.g., 
bagged, from indwelling foley catheter, excess clinical specimen, etc.) 
 Ganciclovir dosing information 
o mg/dose 
o Dosing interval 
o Subject weight 
7.3.4.  Period 5 (Study  Assessment Day 25 thr ough Study Assessment Day 
31)  
Documentation of receipt of PRBC transfusion(s) will be provided on an eCRF.  If the 
study subject has NOT received ≥ 10 PRBC transfusions (see Section 9.3.1), proceed 
with required assessments. 
Required assessments [following confirmation that subject is still receiving ganciclovir 
(e.g., that the ganciclovir has not been permanently discontinued)]:  1) virology blood 
specimens for CMV viral load (required amount of whole blood for CMV PCR is 0.5 mL); 
2) CMV detection from noninvasive urine spec imen (if obtainable); 3) ganciclovir dosing 
information (mg/dose, dosing interval, subject weight). 
Optional assessments (if being drawn for clinical reasons; any laboratory value obtained 
during the window will suffice, with an effort being made to capture the most abnormal value):  1) hematology labs (WBC with differential, hemoglobin, platelet count); 2) chemistry labs (AST, ALT); 3) serum creatinine. 
 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553984] 2015 
 
  
20 Study Assessments ( as described) Optional Assessments* 
Virology blood specimens for CMV viral load Hematology labs (WBC with 
differential, hemoglobin, platelet 
count) 
If obtainable, CMV detection from noninvasive urine specimen (e.g., bagged, from indwelling foley 
catheter, excess clinical specimen, etc.) Chemistry labs (AST, ALT) 
Ganciclovir dosing information (mg/dose, dosing 
interval, subject weight) Serum creatinine 
* If being drawn for clinical reasons; any laboratory value obtained during the window will 
suffice, with an effort being made to capture the most abnormal value 
 
 
7.3.5.  Period 6 (Study  Assessment Day 32 thr ough Study Assessment Day 
38)  
Documentation of receipt of PRBC transfusion(s) will be provided on an eCRF.  If the 
study subject has NOT received ≥ 10 PRBC transfusions (see Section 9.3.1), proceed 
with required assessments. 
Required assessments [following confirmation that subject is still receiving ganciclovir 
(e.g., that the ganciclovir has not been permanently discontinued)]:  1) virology blood 
specimens for CMV viral load (required amount of whole blood for CMV PCR is 0.5 mL); 
2) CMV detection from noninvasive urine spec imen (if obtainable); 3) ganciclovir dosing 
information (mg/dose, dosing interval, subject weight). 
Optional assessments (if being drawn for clinical reasons; any laboratory value obtained 
during the window will suffice, with an effort being made to capture the most abnormal value):  1) hematology labs (WBC with differential, hemoglobin, platelet count); 2) 
chemistry labs (AST, ALT); 3) serum creatinine. 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553985] 2015 
 
  
21  
Study Assessments (as described) Optional Assessments* 
Virology blood specimens for CMV viral load (NOTE: 
if subject weighs < 600 grams, this virology specimen will not be obtained) Hematology labs (WBC with 
differential, hemoglobin, platelet count) 
If obtainable, CMV detection from noninvasive urine 
specimen (e.g., bagged, from indwelling foley 
catheter, excess clinical specimen, etc.) Chemistry labs (AST, ALT) 
Ganciclovir dosing information (mg/dose, dosing 
interval, subject weight) Serum creatinine 
* If being drawn for clinical reasons; any laboratory value obtained during the window will 
suffice, with an effort being made to capture the most abnormal value 
7.4 Final Study Visit 
7.4.1.  Period 7 (Study  Assessment Day 39 thr ough Study Assessment Day 
42) 
Documentation of receipt of PRBC transfusion(s) will be provided on an eCRF.  If the 
study subject has NOT received ≥ 10 PRBC transfusions (see Section 9.3.1), proceed 
with required assessments. 
Required assessments [following confirmation that subject is still receiving ganciclovir 
(e.g., that the ganciclovir has not been permanently discontinued)]:  1) virology blood 
specimens for CMV viral load (required amount of whole blood for CMV PCR is 0.5 mL); 2) CMV detection from noninvasive urine spec imen (if obtainable); 3) ganciclovir dosing 
information (mg/dose, dosing interval, subject weight). 
Optional assessments (if being drawn for clinical reasons; any laboratory value obtained 
during the window will suffice, with an effort being made to capture the most abnormal 
value):  1) hematology labs (WBC with differential, hemoglobin, platelet count); 2) 
chemistry labs (AST, ALT); 3) Serum creatinine. 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553986] 2015 
 
  
22  
Study Assessments (as described) Optional Assessments* 
Virology blood specimens for CMV viral load (NOTE: 
if subject weighs < 650 grams, this virology specimen will not be obtained)  Hematology labs (WBC with 
differential, hemoglobin, platelet count) 
If obtainable, CMV detection from noninvasive urine 
specimen (e.g., bagged, from indwelling foley 
catheter, excess clinical specimen, etc.) Chemistry labs (AST, ALT) 
Ganciclovir dosing information (mg/dose, dosing 
interval, subject weight) Serum creatinine 
* If being drawn for clinical reasons; any laboratory value obtained during the window will 
suffice, with an effort being made to capture the most abnormal value 
7.[ADDRESS_553987]’s therapy be discontinued prematurely, all clinical and laboratory 
evaluations scheduled during the next study visit will be completed on the day the study subject 
is discontinued.  All key endpoints will be evaluated and all randomized study subjects will 
continue to be followed as long as possible and included in the final analysis.  
7.6 Unscheduled Visit  
All subjects enrolled on the study are hospi[INVESTIGATOR_057].  As such, there will not be unscheduled 
visits. 
 
 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553988] 2015 
 
  
23 8 STUDY PROCEDURES/EVALUATIONS 
The study procedures and evaluations are summarized in Appendix A.  In the conduct of this 
study, hospi[INVESTIGATOR_437222] (e.g., pharmacokinetic blood draw 
collection, serum creatinine collection, blood CMV viral load collection, urine collection for 
CMV), under the direction of the site Principal Investigator [INVESTIGATOR_1461].  
8.1 Clinical Evaluations 
8.1.1. Baseline Demographics 
To characterize the study subjects, information will be recorded at the baseline study visit 
(Period 1) following the obtaining of informed consent.  Data collected will include basic 
demographics and birth history (date of birth; gender; race; ethnicity; birth weight; weight at 
enrollment; length in centimeters at enrollment; reason ganciclovir is being administered, gestational age at birth; ganciclovir dose and dosing frequency at time of enrollment; detailed 
ganciclovir dose and dosing frequency since ganciclovir therapy was initiated; manufacturer of 
the ganciclovir lot utilized at the treating facility; and date ganciclovir therapy was initiated).  
8.2 Laboratory Evaluations 
Chemistry labs (serum creatinine) will be draw n on the calendar day that ganciclovir PKs are 
being drawn; required amount of whole blood for serum creatinine is 0.25 mL.  All other 
chemistry labs (serum creatinine, AST, and ALT) and hematology labs (WBC with differential, 
hemoglobin, platelet count) will be recorded on eCRFs if they have been drawn for clinical reasons; any laboratory value obtained during the window will suffice, with an effort being made 
to capture the most abnormal value. 
8.2.1 Special Assays  or Procedures 
Research assays (CMV viral load/resistance and pharmacokinetics will be conducted at the 
respective UAB Central labs). 
[IP_ADDRESS].  CMV Viral Load/Resistance Testing 
Assessment of CMV viral load in whole blood will be conducted at the UAB 
Central Laboratory.  The required amount of whole blood for CMV PCR is 0.5 
mL.  Whole blood will be collected at each study visit from Period 1 through Period 5.  Whole blood will also be collected at the Period 6 study visit if the 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553989] 650 grams. 
Urine collection by [CONTACT_437238] (e.g., bagged, indwelling foley 
catheter, excess clinical specimen, etc.) will be attempted at each study visit.  If 
urine is obtainable, it will be frozen and sent to the UAB Central Laboratory for processing.  If an attempt to obtain urine for CMV detection is unsuccessful, 
study staff will document the failed attempt on a source document.  All 
specimens collected will be sent to the UAB Central Laboratory.
 
 
Viral detection assays will be performed in the UAB Central Laboratory.  These 
assays and tests are in clinical and research use already in the Central Laboratory.  The detection of CMV DNA will be performed using the CMV two primer Taqman assay already employed regularly in our laboratory.  The 
detection limit of our real-time PCR assay, as determined by [CONTACT_437239], is 10genomic equivalents per reaction. The results of 10 different runs on different days are shown in the Table below.  Regression analysis shows a very high correlation coefficient (0.9996) for the 6 log concentration range (see Figure below). 
 
 
genome 
equivalents log(10) # +/10 ct(mean) std 
     
1000000 6 10/10 18.362 0.085609 
100000 5 10/10 21.476 0.155863 
[ZIP_CODE] 4 10/10 24.855 0.187157 
1000 3 10/10 28.321 0.305449 
100 2 10/10 31.869 0.2283 
10 1 10/10 35.283 0.606045 
  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553990] 2015 
 
  
25 
 
 
The amplification efficiency is calculated to be 1.95 with the theoretical maximum 
of 2.0, which would indicate a doubli ng with each PCR cycle.  Each assay 
contains a No Target Control and inhibition is monitored using a house-keepi[INVESTIGATOR_437223], human albumin.  This  2 primer set assay has been used for several 
previous  studies and has been utilized in the Children’s Diagnostic Virology Laboratory for [ADDRESS_553991] 3 cycles, the CMV assay has been within 4 fold of the mean for these unknowns and has 
improved with each group. 
Antiviral resistance will be performed in the UAB Viral Resistance Laboratory.  
Lab testing of viral isolates for ganciclovir resistance will be conducted by a 
standing SOP with a fully characterized  assay.  
[IP_ADDRESS].  Ganciclovir Pharmacokinetics/Adherence 
Assessment of ganciclovir plasma concentrations will be conducted at the UAB  
Central Pharmacokinetic Laboratory.  Ganciclovir concentrations will be obtained 
with one of the Study Assessment Doses 3, 4, 5, 6, 7, or 8 (Window: Study 
Assessment Day 1 through Study Assessment Day 5).  Timepoints for 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553992] 2015 
 
  
26 pharmacokinetic draws are as follows:  0h (immediately prior to IV ganciclovir 
dose; window: -15 min), 1h (immediately after the end of the IV ganciclovir dose; window: +15 min), 2-3h, 5-7h, and 10-12h.  The required amount of whole blood 
for plasma ganciclovir determination at each timepoint is 200 L (0.2 mL).  
Specimens will be processed to separate the plasma, which will be shipped to 
the UAB  Central Pharmacokinetic Laboratory. 
If desired by [CONTACT_437240] ≥ 575 grams at that 
time, ganciclovir concentrations may be evaluated again around one dose in this 
assessment window (Study Assessment Day 18 through Study Assessment Day 
24).  Timepoints for pharmacokinetic draws are as follows:  0h (immediately prior to IV ganciclovir dose; window: -15 min), 1h (immediately after the end of the IV ganciclovir dose; window: +15 min), 2-3h, 5-7h, and 10-12h.  The required 
amount of whole blood for plasma ganciclovir determination at each timepoint is 
200 L (0.2 mL).  Specimens will be processed to separate the plasma, which 
will be shipped to the UAB  Central Pharmacokinetic Laboratory.  If subject 
weighs < 575 grams, the second set of PK draws cannot be performed. 
A rapid, sensitive and specific high performance liquid chromatographic (HPLC) 
assay is used for the determination of ganciclovir in 200uL of human plasma.  
The UV detector, set to monitor the 270nm wavelength, provides adequate sensitivity with minimal interference from endogenous matrix components.  The 
calibration curves are linear for ganciclovir over the range of 10 to 10,000 ng/mL. 
 
8.2.2 Specimen Preparation,  Handling, and Shippi[INVESTIGATOR_007] 
[IP_ADDRESS] Instructions for Specimen Preparation, Handling, and Storage 
Specific instructions on specimen preparation, handling and storage will be provided in the 
Manual of Procedures for this study. 
[IP_ADDRESS] Specimen Shipment 
Specific instructions on specimen shippi[INVESTIGATOR_437224]. 
 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553993] since enrollment (for the Period 1 documentation) or since the last recording (for 
documentation for Periods 2-7).  A PRBC transfusion is defined as ≥ 10 mL/kg of PRBCs within 
a 24 hour period. 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553994] (AESIs).  Information to be collected includes event 
description, time of onset, clinician’s assessment of severity, relationship to blood draw 
(assessed only by [CONTACT_8703] a diagnosis, which would include MD or DO), and time of resolution/stabilization of the event.  AEs will be followed to 
adequate resolution.  
Any other adverse events that meet the reporting requirements of the Institutional Review Board 
will be documented as AESIs, and reported to Protoc ol Chair, DMID Medical Officer, Medical 
Monitor and the Clinical Project Manager. 
9.1 Safety Reporting:  Adverse E vents of Special Interest (AESI) 
The investigator must also report the following AESI on the AESI case report form: 
o AEs associated with blood draws 
o All adverse events that meet the reporting r equirements of the Institutional Review Board 
(which will also be reported to Protocol Chai r, DMID Medical Officer, Medical Monitor and 
the Clinical Project Manager). 
o  
9.[ADDRESS_553995]. 
Subjects who experience significant problems with blood draws may be withdrawn from any 
future sampling.  Transfusions are expected in hospi[INVESTIGATOR_437219].  One study 
reported that extremely premature neonates receiv e an average of 5.2 ± 4.[ADDRESS_553996] reported similar numbers of transfusions in this 
population.32,33  It is possible that even higher numbers of transfusions might be experienced in 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553997] receives ≥ 10 PRBC transfusions during the course of the study, 
all future study-related blood draws will not be performed. 
9.3.2 Discontinuation of  Study Enrollment Pending Sponsor Review 
DMID may interrupt study testing and/or study ent ry at any time if medically indicated.  To 
minimize risk, the Protocol Chair, DMID M edical Officer, and Medical Monitor will review 
cumulative safety data.   
Study enrollment and dosing will be stopped, and an ad hoc review will be performed if: 
 X of the first Y subjects enrolled have more than 5 packed red blood cell (PRBC) 
transfusions during their period of time on the study, according to the table below.  For a 
PRBC transfusion to be counted toward this halting rule, it must involve ≥ 10 mL/kg of 
PRBCs administered within a 24 hour period of time. 
 
Number 
enrolled 
(Y) Stop/Investigate 
when number 
with events 
equals this 
number (X) type I 
error power 
when 
mean=7 
4 4 0.0218 0.2391 
5 5 0.0084 0.1672 
6 5 0.0341 0.4186 
7 6 0.0151 0.3279 
8 6 0.0406 0.5500 
9 7 0.0196 0.4609 
10 7 0.0438 0.6477 
11 8 0.0225 0.5675 
12 8 0.0450 0.7218 
13 9 0.0242 0.6522 
14 9 0.0450 0.7787 
15 10 0.0251 0.7195 
16 10 0.0442 0.8230 
17 11 0.0254 0.7732 
18 11 0.0429 0.8578 
19 12 0.0253 0.8162 
20 12 0.0414 0.8853 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_553998] 2015 
 
  
30 21 13 0.0248 0.8506 
22 13 0.0397 0.9072 
23 14 0.0242 0.8784 
24 14 0.0378 0.9246 
25 15 0.0234 0.9008 
26 15 0.0360 0.9387 
27 16 0.0226 0.9189 
28 16 0.0342 0.9500 
29 16 0.0496 0.9701 
30 17 0.0324 0.9592 
31 17 0.0465 0.9756 
32 18 0.0307 0.9666 
 
This halting rule is supported by [CONTACT_437241] 5.2 ± 4.[ADDRESS_553999] receiving more than 5 PRBC 
transfusions is 0.384 (or 38.4%).  If the halting rule is to stop the study when exactly 4 subjects 
receive more than 5 transfusions, then the probability of halting the study based on the given assumptions is 0.001 (or 0.1%) using a Binomial distribution with n=32 and probability of 
success equal to 0.384. 
9.4 DMID Safety Oversight  
DMID (medical officer, medical monitor and clinic al project manager), the Protocol Chair, the 
UAB Central Unit, and an independent safety monitor (ISM) with expertise in pharmacology will: 
 Monitor ganciclovir systemic exposures achi eved with the clinical administration of 
ganciclovir.   
 Review the safety information when a halting rule is met. 
 Review AESIs on a regular basis. 
  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554000] use error that is suspected to be associated with the use of an FDA-regulated drug, biologic, medical device or 
dietary supplement.  This system is for the r eporting of adverse events noted spontaneously in 
the course of clinical care, and not for events that occur during clinical trials under an 
Investigational New Drug (IND) application.   
The MedWatch Website, http://www.fda.gov /Safety/MedWatch/HowToReport/ucm085568.htm 
can be used to voluntarily report a serious adverse event, product quality problem or product 
use error that is suspected to be associated with the use of an FDA-regulated drug, biologic, 
medical device, dietary supplement or cosmetic .  FDA uses these data to maintain safety 
surveillance of all FDA-regulated products.  A health care professional report may be the critical 
action that prompts a modification in use or design of the product, improves the safety profile of 
the drug or device and leads to increased patient safety. 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554001] protection, study procedures, 
laboratory procedures, study intervention administr ation, and data collection processes are of 
high quality and meet sponsor, GCP/ICH, and regulatory guidelines, and that the study is conducted in accordance with the protocol and study manuals.  NIAID/ DMID, the sponsor of 
this study, or its designee will conduct site monitoring visits as detailed in the monitoring plan.  A 
Clinical Monitoring Plan will be developed to include specifics about the monitoring, including a description of the number and type of subjects monitored, frequency of visits, tasks completed 
during the visits, and the different types of visits that will be used during the monitoring.  The 
monitoring plan will be a risk based assessment. 
Site visits typi[INVESTIGATOR_437225].  More frequent sites visits may 
be made if needed.  Monitoring visits will include, but are not limited to, review of regulatory 
files, case report forms, informed consent forms, medical and laboratory reports, and protocol compliance.  Study monitors will meet with inve stigators to discuss any problems and actions to 
be taken and document visit findings and discussions. 
Every effort will be made to maintain the anonymi ty and confidentiality of subjects during this 
study. However, because of the experimental nature of this sampling study, the Investigator agrees to allow representatives of the sponsor as well as authorized representatives of the Food 
and Drug Administration, or other Regulatory agencies or the UAB Central Unit, to inspect the 
facilities used in this study and to inspect, for purposes of verification, the hospi[INVESTIGATOR_114741].  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554002] 2015 
 
  
33 11 STATISTICAL CONSIDERATIONS 
11.1 Study Hypotheses 
Our primary hypothesis is that ganciclo vir pharmacokinetics and pharmacodynamics in 
premature infants with postnatally or congenitally acquired CMV infection differ from those in 
term neonates and older infants.  
11.2 Sample Size Considerations 
The primary outcome used for power analysis is the area under the curve for 12 hours (AUC12) 
following 6 mg/kg of ganciclovir.  In a one-way ANOVA design, we would like to compare the 
means of 4 groups (see below) with sample sizes of approximately 8, 8, 8, and 8 (32 total 
subjects enrolled across the four cohorts).  If the means of the AUC12 of the [ADDRESS_554003] deviation of 10, these mean differences 
(equivalent to an effect size of 0.72) will be detected at 83% power using an F test with 0.[ADDRESS_554004] size given the differences 
in means as described above, and the power of detecting such a difference/effect size.  If 
estimating the AUC without regard to the groups, the margin of errors associated with a 95% confidence interval assuming different standard deviation values and a sample size of [ADDRESS_554005] Deviation S=8 S=9 S=10 S=[ADDRESS_554006] Size 0.81 0.72 0.64 0.59 
Power 96% 91% 83% 75% 
Margin of Error 2.33 2.62 2.91 3.20 
 
The above parameter values were hypothesized based on results from other studies.
25,34  It is 
worth noting that there are no PK data in this population and the results are likely to be different from other studies due to the maturational changes. 
Following enrollment, subjects will be stratified by [CONTACT_437242]:  1) ≤ 27 weeks 6 days gestational age at birth and ≤ 30 days chronologic age at study 
enrollment; 2) ≤ 27 weeks 6 days gestational age at birth and > 30 days chronologic age at 
study enrollment; 3) ≥ 28 weeks 0 days gestational age at birth and ≤ 30 days chronologic age 
at study enrollment; 4) ≥ 28 weeks 0 days gestational age at birth and > 30 days chronologic 
age at study enrollment.  The total sample size across these four cohorts is 32 subjects.  
Enrollment of an additional 2-3 subjects may be allowed for operational reasons.  If the 32 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554007] 2015 
 
  
34 subjects enrolled are not balanced across the 4 groups, we instead will look at the correlation 
between gestational age at birth. With 32 subjects, the margin of errors of a 95% confidence interval for estimating the correlation given the observed correlation values are given below. 
 
Correlation 0.[ADDRESS_554008] non-compartmental 
techniques will be used initially to estimate pharmacokinetic parameters derived from the ganciclovir concentration-time data.  The resource utilized for pharmacokinetic analysis is 
WinNonlin version 5.3, Pharsight Corporation, Mountain View, CA. 
11.3 Planned Interim Analyses (if applicable) 
There are no planned interim analyses or safety reviews for this trial.  
11.4 Final Analysis Plan 
Primary analysis: To compare the ganciclovir pharmacokinetics and pharmacodynamics as 
measured by [CONTACT_12265]12 in premature infants wi th postnatally or congenitally acquired CMV 
infection differ from those in term neonates and older infants, we will construct 95% confidence 
intervals around the mean AUC 12 for the subjects in this study and compare these means 
across the groups.  If there are not enough subjects in the groups, we will use the actual gestational age and correlate it with the AUC
12 by [CONTACT_437243] a fitting 
regression model.  Additional pharmacokinetic parameters that compose analyses for 
secondary endpoints include Cmax, T1/2,CL, and VD.  For measures that are repeated over 
time, we will utilize mixed models for repeated measures.  In addition to being able to compare these outcomes for the different groups, we can also look into how these measures change over 
time and adjust for covariates.  
Ganciclovir pharmacokinetic parameters will in itially be determined using non-compartmental 
analysis (WinNonlin v5.3) for each in dividual subject.  The parameters (AUC
12, CL, Vd, etc.) will 
be summarized and further used for exploratory phar macodynamic analysis.  We will also apply 
pharmacokinetic models to the concentration-time data, either individually or using a population approach.  We may also pool these data with prior CASG [ADDRESS_554009] and the 
nature of those data.  Concentration-time data will be analyzed using nonlinear mixed-effects in 
ADAPT 5.0.  If a population approach is employed, this will give us the opportunity to explore 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554010] 2015 
 
  
35 relationships between ganciclovir exposure and multiple covariates, such as gestational age, 
weight, renal function, etc.  
A 95% confidence interval will be constructed to evaluate the mean changes in the log of the 
viral load between baseline (day 1) and weeks 1, 2, 3, 4, 5, and 6.  Area under the curve will be 
calculated for each subject’s CMV viral load measurement utilizing the trapezoidal rule.  These AUCs will be calculated over the entire course of drug administration.  Spearman’s correlations 
will be given for each AUC estimation and also for the AUC after baseline viral load (VL) 
adjustment.  Analysis of variance will be used to investigate whether groupi[INVESTIGATOR_437226] (undetected, 100-1000, 1000-[ZIP_CODE] and ≥ [ZIP_CODE]) would indicate any PD relationships.  In 
addition, changes in CMV viral load from baseline over time (weeks 1 through 6) will be 
correlated with PK parameters.  These data will  provide the framework for all PD analyses, 
where ganciclovir exposures variables will be correlated with the response variables using linear 
or maximum effect PD models. 
Secondary analyses: To investigate the association of secondary outcomes namely, 
neutropenia, CMV in urine, viral load and resistance to ganciclovir, with plasma concentration, 
we will utilize inference methods based on Generalized Estimating Equations (GEE) which 
models repeated binary data. As in the primary analysis, GEE will enable us to compare groups, 
investigate changes of outcomes over time, and adjust for any covariates.  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554011] 2015 
 
  
36 12 SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS 
The site will maintain appropriate medical and research records for this trial, in compliance with 
ICH E6, Section 4.9 and regulatory and institutional requirements for the protection of confidentiality of subjects. As part of participating in a DMID-sponsored, DMID-affiliated, or 
manufacturer-sponsored study, the site will permit authorized representatives of the sponsor(s), 
DMID, the UAB Central Unit and regulatory agencies to examine (and when required by [CONTACT_1289], to copy) clinical records for the purposes of quality assurance reviews, audits, and evaluation of the study safety and progress. 
Documentation of source data is necessary for the reconstruction, evaluation, and validation of 
clinical findings, observations, and other activities  during a clinical trial. Source data are all 
information, original records of clinical findings, observations, or other activities in a clinical trial 
necessary for the reconstruction and evaluation of the trial. Examples of these original 
documents and data records include, but are not limited to, Source Document Worksheets, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjects’ evaluation 
checklists, pharmacy dispensing records, record ed data from automated instruments, copi[INVESTIGATOR_5117], microfiches, photographic negatives, microfilm or magnetic media,  x-rays, and subject files and records kept 
at the pharmacy, at the laboratories, and medico-technical departments involved in the clinical 
trial.  Source documentation serves to substantiate the integrity of trial data, confirms observations that are recorded, and confirm the existence of study participants.  This standard 
also serves to ensure data quality by [CONTACT_258909], complete, and accurate.  Sites that are participating in this trial should consult the MOP, and DMID/NIAID Source Document Standards (most current version) for specific 
instruction and forms. 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554012] 2015 
 
  
37 13 QUALITY CONTROL AND QUALITY ASSURANCE 
The study site will implement a quality management plan.  The quality management procedures 
are described herein, as well as in the Manual of Procedures and the study site quality management plan (QMP).  Per the QMP, data will be evaluated for compliance with the protocol 
and accuracy in relation to source documents.  The study will be conducted in accordance with 
procedures identified in the protocol.  Items to be reviewed include, but are not limited to: eligibility (including informed consent), AE repor ting, study/clinical endpoints, follow-up visits, 
regulatory documents, missed visits, and review of clinical records.  Data that will be reviewed, 
who is responsible for implementation, and the schedule for internal reviews will be specified or referenced in the quality management plan.   
 
The  study monitors will verify that the clinical trial is conducted and data are generated, documented, and reported in compliance with the protocol, ICH E6(R1), and the applicable regulatory requirements.  Reports will be submitt ed to DMID and UAB on monitoring activities.  
The study site research team will provide direct access to all trial-related sites, source 
data/documents, and reports for the purpose of monitoring and auditing by [CONTACT_114809]. 
 
The UAB Statistical and Data Coordinating Cent er will implement quality control procedures 
beginning with the data entry system and generate data quality control checks that will be run 
on the database within [ADDRESS_554013] data.  
All of these procedures and processes are described in detail in the DMID 11-0067 Data Management Plan (DMP) specific for this protocol .  The DMP defines and provides instructions 
regarding the conduct of the data management processes, describing in detail the following: the 
work to be performed, the responsible individuals/groups, applicable SOPs and Guidelines, and required documentation.  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554014] 2015 
 
  
38 14 ETHICS/PROTECTION OF HUMAN SUBJECTS 
14.[ADDRESS_554015] 
The investigator will ensure that this study is conducted in full conformity with the principles set 
forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research of the US National Commi ssion for the Protection of Human Subjects of 
Biomedical and Behavioral Research (April 18, 1979) and codified in 45 CFR Part 46 and/or the 
ICH E6; 62 Federal Regulations [ZIP_CODE] (1997). 
14.[ADDRESS_554016] FDA-regulated studies.  In the 
[LOCATION_002] and in other countries, only institutions holding a current US Federalwide Assurance (FWA) issued by [CONTACT_437244]. 
 
This protocol, informed consent documents, rele vant supporting information, and all types of 
volunteer recruitment or advertisement information will be submitted to the Institutional Review 
Board (IRB) for review and must be approved before the study is initiated.  Any amendments to 
the protocol must also be approved by [CONTACT_32629] B prior to implementing changes in the study.  
 The investigator is responsible for keepi[INVESTIGATOR_114742], but in any case at least once per 
year.  The investigator must also keep the IRB informed of any significant AEs.  
All IRB approved documents as well as rele vant study correspondence should be copi[INVESTIGATOR_114743]. 
For this study, clinical sites will have the opportunity to participate in a Facilitated Central IRB 
process supported by [CONTACT_437245].  
Participating sites will be provided with detailed instructions on required responsibilities for participating an OHRP compliant Facilitated IRB.  
14.[ADDRESS_554017] be documented in the medical records, clinic 
chart, and/or research chart.  The consent form must be signed and dated by [CONTACT_423]’s 
parent(s)/legal guardian(s) before participation in the study.  A copy of the signed consent form must be provided to the subject’s parent(s)/legal guardian(s).  Signed consent forms must 
remain in each study participants study file and must be available for verification by [CONTACT_33483].  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554018]’s parent(s)/legal guardian(s).  A 
signed informed consent document will be obtained from each subject’s parent(s)/legal 
guardian(s) prior to entry into this study.  At any time during participation in the protocol, if new information becomes available relating to risks,  AEs, or toxicities, this information will be 
provided orally or in writing to all enrolled or  prospective subject’s parent(s)/legal guardian(s). 
Documentation will be provided to the IRB and, if necessary, the informed consent will be 
amended to reflect any relevant information. 
An investigator shall seek such consent only under circumstances that provide the subject’s 
parent(s)/legal guardian(s) sufficient opportunity to consider whether or not to participate and 
that minimize the possibility of coercion or undue influence. The information that is given to the subject’s parent(s)/legal guardian(s) shall be in language understandable to the subject’s parent(s)/legal guardian(s). 
Subject’s parent(s)/legal guardian(s) will sign the informed consent document prior to any 
procedures being done specifically for the study.  Subject’s parent(s)/legal guardian(s) should have the opportunity to discuss the study with thei r family, friends or pers onal physician, or think 
about it prior to agreeing to participate.  Subject’s parent(s)/legal guardian(s) may withdraw 
consent at any time throughout the course of the trial.  A copy of the informed consent 
document will be given to the subject’s parent(s)/legal guardian(s) for their records.  The rights and welfare of the subjects will be protected by [CONTACT_437246].  
14.3.1 Informed Consent/Assent Process (in Case of a Minor) 
If required by [CONTACT_779]’s IRB, the parent or legal guardian will sign a waiver of assent for the 
minor due to the study participant’s age.  Assent age will be determined by [CONTACT_1036].  Appropriate documentation will be required for subjects who are the age of assent, whether mature enough to read and capable of providing signed assent, or whether too young to read 
but capable of providing verbal assent, as determined by [CONTACT_258911] 
45CFR46.  Local IRBs will review and assign the risk level.  
14.4 Exclusion of Women, Mino rities, and Children (Special 
Populations) 
This study will be conducted solely in premat ure infants.  The study will not exclude young 
children, females, or minorities.  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554019] parties other than those noted below is prohibited.  The results of the research study 
may be published, but study participant’s names or identities will not be revealed.  Records will remain confidential.  To maintain confidentiality, the principal investigators at each site will keep 
records in locked cabinets or locked rooms and the results of tests will be coded to prevent 
association with volunteers’ names.  Data entered into computerized files will be accessible only by [CONTACT_437247] t he study and will be encoded.  Data received by 
[CONTACT_437248].  However, subject specific 
information will be available to the clinical monitors, to the FDA and to health authorities where provided by [CONTACT_2371]. .   
 
The study investigator is obliged to provide the UAB Central Unit and NIAID/DMID with 
complete test results and all data developed in this study.  The NIAID/DMID or UAB  may 
disclose this information to appropriate regulatory authorities or clinical practice management 
groups (such as Pediatric Infectious Disease Society) as deemed necessary.     
Subject-specific information may be provided to other appropriate medical personnel only with 
the study participant’s parent/legal guardian permission.  To ensure compliance with current ICH guidelines, data generated by [CONTACT_351871], the NIAID/DMID, UAB Central Unit 
personnel, and the IRB/IEC for each study site. 
14.6 Study Discontinuation 
Therapy is not being provided by [CONTACT_437249].  Therefore, there is no 
procedure for subjects to continue therapy if the study is discontinued.  
14.7 Future Use of Stored Specimens 
Some of the specimens obtained from study participants during this study will be stored 
indefinitely in the UAB Central Laboratory at the University of Alabama at Birmingham and may 
be used in future CMV research.  These specimens will be labeled with a code number and not 
with the study participant’s name.  At the time of consent for study participation, study participant’s parent/legal guardian will have the opportunity to either agree to have their 
specimens used in future CMV research or decline to have their specimens used in future CMV 
research.  The study participant’s parent/legal guardian will indicate his/her preference by [CONTACT_171909], “Future Use of Specimens”.  Non-protocol designated, future testing of samples will be 
performed only on samples from study participants who have consented for future testing of samples.  These specimens will only be utilized to better understand the natural history of CMV 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554020] ablished according to OHRP guidelines ensuring 
that codes or other personally identifying links will not be distributed to future researchers. 
The specimens will be stored indefinitely in the UAB Central Laboratory at the University of 
Alabama at Birmingham.  CMV specimens from  study participants will be labeled and coded 
without study participant’s identifiers.  If the study participant’s parent/legal guardian has 
indicated in the signed consent form that he/she does not agree to allow the future use of specimens for future CMV research, then his/her child’s specimens will be destroyed at the 
completion of the study.  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554021] KEEPI[INVESTIGATOR_437227], completeness, legibility, and timeliness 
of the data reported. 
Electronic case report forms (eCRFs) will be developed by [CONTACT_114818].  The eCRFs will be provided electronically by [CONTACT_114819].  
Original data will be recorded on source documents (e.g., medical records, research progress notes, Source Document Worksheets documenting research related procedures).  The DMID 
11-[ADDRESS_554022]’s source documents. 
15.[ADDRESS_554023] be reviewed by [CONTACT_093]’s research team, under the supervision of the 
investigator, who will ensure that they are accurate and complete.  All data must be supported by [CONTACT_18412], which will remain available for review by [CONTACT_114821].  Adverse events must be graded, assessed for intensity and causality, and reviewed 
by [CONTACT_114822].      
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site PI.  During the study, the investigator must maintain complete and accurate 
documentation for the study. 
The UAB Central Unit and Statistical and Data Coordinating  will be responsible for data 
management, quality review, analysis of the study data, and writing of the clinical study report.  
These tasks are detailed in the DMID 11-0067 DMP. 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554024] 2015 
 
  
43 15.2 Data Capture Methods 
Clinical and laboratory data will be entered into a 21 CRF Part 11 compliant electronic Data 
Entry System (eDES)  provided by [CONTACT_437250].  The data 
system includes password protection and inte rnal quality checks, such as automated range 
checks, to identify data that appear to be inconsistent, incomplete, or inaccurate.  
15.3 Types of Data 
Data for this study will include clinical laboratory, pharmacokinetic, and virologic results, and 
clinical and outcome measures (e.g., PK, weight, and virology). 
15.4 Timing/Reports 
There are no planned interim analyses or safety reviews for this trial.  Stoppi[INVESTIGATOR_437228] 9.5.  Following enrollment and PK assessments on the first four study subjects, safety and pharmacokinetic data will be summarized and reviewed by [CONTACT_1034] 
(e.g., the DMID medical officer and the DMID medi cal monitor), Protocol Chair, the UAB Central 
Unit, and an independent pharmacology monitor.  The frequency of future data reviews will be determined at that time. 
15.[ADDRESS_554025] 2 years following completion of the study.  No study records shall be destroyed without prior authorization from the UAB Central Unit and NIAID/DMID.  These 
documents should be retained for a longer period, howev er, if required by [CONTACT_427].  It is 
the responsibility of the sponsor to notifiy the UAB Central Unit, which will notify the investigators, when these documents no longer need to be retained. 
15.[ADDRESS_554026] be approved by [CONTACT_171912]/DMID prior to 
seeking approval from the IRB/IEC.  Each investigator will be responsible for enrolling only 
those study participants who have met protocol eligibility criteria. 
A protocol deviation is any noncompliance with t he clinical trial protocol, GCP, or Manual of 
Procedures requirements.  The noncompliance may be either on the part of the study 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554027] 2015 
 
  
44 participant, the investigator, or the study site staff.  As a result of deviations, corrective actions 
are to be developed by [CONTACT_3483].  
These practices are consistent with ICH E6 GCP sections: 
4.[ADDRESS_554028] be pr omptly reported to the UAB Central Unit.  UAB 
will report all deviations to DMID in accordance with DMID’s instructions. 
All deviations from the protocol must be address ed in the source documents.  A completed copy 
of the DMID protocol deviation form must be maintained in the regulatory file (Project Notebook 
or designated location) as well as in the subject’s source documents. A log of protocol deviation will be maintained in the Project Notebook. Protocol deviations must be sent to the local IRB per 
the IRB’s guidelines.  The site PI/study staff is responsible for knowing and adhering to their 
IRB/IEC requirements. 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554029] 2015 
 
  
45 16 PUBLICATION POLICY 
Following completion of this study, the investigators are expected to publish the results in a 
scientific journal.  All research reports and other publications resulting from the work completed in this protocol shall: 
 Acknowledge the support of the National Institutes of Health whenever publicizing the 
results from this clinical trial in any media by [CONTACT_114826]: 
o Be submitted to the Project Director in the form of advance copi[INVESTIGATOR_114745]. 
o Be furnished in a list of publications resulting from the research as part of the annual 
progress report submitted to the principal investigator. 
 
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted 
a trials-registration policy as a condition for publicati on.  This policy requires that all clinical trials 
be registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_38082].  Other biomedi cal journals are considering adopting similar 
policies. 
Unless exempted, this trial will be registered prior to enrollment of study subjects.  It is the 
responsibility of the study’s PI (e.g., [CONTACT_32246] berlin) to register the non-exempted trials and post 
results in compliance with Public Law 110-85, the Food and Drug Administration Amendments 
Act of 2007 (FDAAA). 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554030] 2015 
 
  
46 17 LITERATURE REFERENCES 
 
1. Stagno S, Whitley RJ. Herpesvirus infections of pregnancy. Part I: Cytomegalovirus and 
Epstein-Barr virus infections. N Engl J Med . 1985;313:1270-4. 
2. Boppana SB, Fowler KB, Vaid Y, et al. Neuroradiographic findings in the newborn period 
and long-term outcome in children with symptomatic congenital cytomegalovirus 
infection. Pediatrics . 1997;99:409-14. 
3. Boppana SB, Pass RF, Britt WJ, et al. Symptomatic congenital cytomegalovirus 
infection: neonatal morbidity and mortality. Pediatr Infect Dis J . 1992;11:93-9. 
4. Dahle AJ, Fowler KB, Wright JD, et al. Longitudinal investigation of hearing disorders in 
children with congenital cytomegalovirus. Journal of the American Academy of 
Audiology . 2000;11:283-90. 
5. Fowler KB, Boppana SB. Congenital cytomegalovirus (CMV) infection and hearing 
deficit. J Clin Virol . 2006;35:226-31. 
6. Fowler KB, McCollister FP, Dahle AJ, et al. Progressive and fluctuating sensorineural 
hearing loss in children with asymptomatic  congenital cytomegalovirus infection. J 
Pediatr . 1997;130:624-30. 
7. Rivera LB, Boppana SB, Fowler KB, et al. Predictors of hearing loss in children with 
symptomatic congenital cytomegalovirus infection. Pediatrics . 2002;110:762-7. 
8. Stronati M, Lombardi G, Di Comite A, et al. Breastfeeding and cytomegalovirus 
infections. J Chemother . 2007;[ADDRESS_554031] 2:49-51. 
9. Vochem M, Hamprecht K, Jahn G, et al. Transmission of cytomegalovirus to preterm 
infants through breast milk. Pediatr Infect Dis J . 1998;17:53-8. 
10. Maschmann J, Hamprecht K, Dietz K, et al . Cytomegalovirus infection of extremely low-
birth weight infants via breast milk. Clinical Infectious Diseases . 2001;33:1998-2003. 
11. Takahashi R, Tagawa M, Sanjo M, et al. Severe postnatal cytomegalovirus infection in a 
very premature infant. Neonatology . 2007;92:236-9. 
12. Vancikova Z, Kucerova T, Pelikan L, et al. Perinatal cytomegalovirus hepatitis: to treat or 
not to treat with ganciclovir. J Paediatr Child Health . 2004;40:444-8. 
13. Bradshaw JH, Moore PP. Perinatal cytomegalov irus infection associated with lung cysts. 
Journal of Paediatrics & Child Health . 2003;39:563-6. 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554032] 2015 
 
  
47 14. Hsu ML, Cheng SN, Huang CF, et al. Perinatal cytomegalovirus infection complicated 
with pneumonitis and adrenalitis in a premature infant. Journal of Microbiology, 
Immunology & Infection . 2001;34:297-300. 
15. Neuberger P, Hamprecht K, Vochem M, et al. Case-control study of symptoms and 
neonatal outcome of human milk-transmitted cy tomegalovirus infection in premature 
infants. J Pediatr . 2006;148:326-31. 
16. Kothari A, Ramachandran VG, Gupta P. Cytomegalovirus infection in neonates following 
exchange transfusion. Indian J Pediatr . 2006;73:519-21. 
17. Mussi-Pi[INVESTIGATOR_437229], Yamamoto AY, do Carmo Rego MA, et al. Perinatal or early-
postnatal cytomegalovirus infection in preterm infants under 34 weeks gestation born to 
CMV-seropositive mothers within a high-seroprevalence population. J Pediatr . 
2004;145:685-8. 
18. Yasuda A, Kimura H, Hayakawa M, et al. Evaluation of cytomegalovirus infections 
transmitted via breast milk in preterm infants with a real-time polymerase chain reaction assay. Pediatrics . 2003;111:1333-6. 
19. Vollmer B, Seibold-Weiger K, Schmitz-Salue C, et al. Postnatally acquired 
cytomegalovirus infection via breast milk: effects on hearing and development in preterm 
infants. Pediatr Infect Dis J . 2004;23:322-7. 
20. Hamprecht K, Maschmann J, Jahn G, et al. Cytomegalovirus transmission to preterm 
infants during lactation. J Clin Virol . 2008;41:198-205. 
21. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in 
symptomatic congenital cytomegalovirus diseas e involving the central nervous system: a 
randomized, controlled trial. J Pediatr . 2003;143:16-25. 
22. Oliver SE, Cloud GA, Sanchez PJ, et al. Neurodevelopmental outcomes following 
ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the 
central nervous system. J Clin Virol . 2009;[ADDRESS_554033] 4:S22-6. 
23. Investigator's Brochure. Ro107-9070 (Valcyte , Valganciclovir). 2002. 
24. Trang JM, Kidd L, Gruber W, et al. Linear single-dose pharmacokinetics of ganciclovir in 
newborns with congenital cytomegalovirus infections. Clinical Pharmacology & 
Therapeutics . 1993;53:15-21. 
25. Kimberlin DW, Acosta EP, Sanchez PJ, et al. Pharmacokinetic and pharmacodynamic 
assessment of oral valganciclovir in the treatment of symptomatic congenital 
cytomegalovirus disease. J Infect Dis . 2008;197:836-45. 
26. Englund JA, Fletcher CV, Balfour HH, Jr. Acyclovir therapy in neonates. J Pediatr . 
1991;119:129-35. 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554034] 2015 
 
  
48 27. Zhou XJ, Gruber W, Demmler G, et al. Population pharmacokinetics of ganciclovir in 
newborns with congenital cytomegalovirus infections. Antimicrob Agents Chemother . 
1996;40:2202-5. 
28. Whitley RJ, Cloud G, Gruber W, et al. Ganc iclovir treatment of symptomatic congenital 
cytomegalovirus infection: results of a phase II study. J Infect Dis . 1997;175:1080-6. 
29. Acosta EP, Brundage RC, King JR, et al. Ganciclovir population pharmacokinetics in 
neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther . 2007;81:867-72. 
30. Trang JM, Kidd L, Gruber W, et al. Linear single-dose pharmacokinetics of ganciclovir in 
newborns with congenital cytomegalovirus infections. Clin Pharmacol Ther . 1993;53:15-
21. 
31. Ohls RK, Ehrenkranz RA, Wright LL, et al. Effects of early erythropoietin therapy on the 
transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics . 2001;108:934-42. 
32. Kirpalani H, Whyte RK, Andersen C, et al. The Premature Infants in Need of Transfusion 
(PI[CONTACT_110586]) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) 
transfusion threshold for extremely low birth weight infants. J Pediatr . 2006;149:301-307. 
33. von Lindern JS, Khodabux CM, Hack KE, et al. Long-term outcome in relationship to 
neonatal transfusion volume in extremely premature infants: a comparative cohort study. BMC Pediatr . 2011;11:48. 
34. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its 
oral administration and from its prodrug, valganciclovir, in solid organ transplant 
recipi[INVESTIGATOR_840]. Clin Pharmacokinet . 2005;44:495-507. 
 
  
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554035] 2015 
 
  
 _____________________________________________________________________________________________  
49 SUPPLEMENTS/APPENDICES 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554036] 2015 
 
  
 _____________________________________________________________________________________________  
50 APPENDIX A: SCHEDULE OF EVENTS 
(FOLLOWING ACQUISITION OF INFORMED CONSENT) 
Table 1. Schematic of Study Design for Gan Premie 
NOTE: Required Studies in Black Font, Optional Studies in Blue Font  
 Period 1 
(Study 
Assessment Day 1 through 
Study 
Assessment Day 3) Period 2 
(Study 
Assessment Day 4 through Study 
Assessment
Day 10)
a Period 3 
(Study 
Assessment Day 11 through Study 
Assessment
Day 17)
a Period 4 
(Study 
Assessment Day 18 through 
Study 
Assessment Day 24)
a Period 5 
(Study 
Assessment Day 25 through 
Study 
Assessment Day 31)
a Period 6 
(Study 
Assessment Day 32 through Study 
Assessment
Day 38)
a Period 7 
(Study 
Assessment Day 39 through 
Study 
Assessment Day 42)
a 
Baseline demographics
b Xc       
Hematology 
labsd Xc,e Xe Xe Xe Xe Xe Xe 
Chemistry 
labsf Xc,e Xe Xe Xe Xe Xe Xe 
Creatinine Xg Xe Xe Xe Xe Xe Xe 
Ganciclovir 
pharmacokin
etics Xh  Xi,j    
Virology 
blood 
specimens for CMV viral load
k Xl Xl Xl Xl Xl Xl,m Xl,n 
CMV 
detection 
from 
noninvasive urine specimen X
o Xo Xo Xo Xo Xo Xo 
Ganciclovir 
dosing information X
p Xp Xp Xp Xp Xp Xp 
PRBC 
transfusion 
assessment Xq Xq Xq Xq Xq Xq Xq 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554037] 2015 
 
  
 _____________________________________________________________________________________________  
51 Assessment 
for AEs or 
SAEs  X X X X X X 
Total volume 
of blood required for study procedures 1.75 mL 0.5 mL 0.5 mL 0.5 mL 
or 1.5 
mL
i 0.5 mL 0.5 mL 0.5 mL 
a) Data and specimens in this column to be captured if subject still receiving ganciclovir as clinical treatment 
b) Gestational age at delivery, date of birth, day of life at  initiation of IV ganciclovir therapy, gender, race, 
ethnicity, birth weight, weight at enrollment, length in  centimeters at enrollment, reason ganciclovir being 
administered, ganciclovir dose and dosing frequency, manu facturer of the ganciclovir lot utilized at the 
treating facility, date gancic lovir therapy was initiated 
c) Window: Birth through Study Assessment Day 3) 
d) WBC with differential, hemoglobin, platelet count.  Optional laboratory draws are not required by [CONTACT_12695], and so no documentation on a source document will be required. 
e) If being drawn for clinical reasons; any laboratory value obtained during the window will suffice, with an effort 
being made to capture the most abnormal value.  Optiona l laboratory draws are not required by [CONTACT_760], 
and so no documentation on a source document will be required. 
f) AST, ALT.  Optional laboratory draws are not required by [CONTACT_760], and so no documentation on a 
source document will be required. 
g) To be drawn on the calendar day that ganciclovir PKs  are being drawn.  Study related laboratory draws will 
be delayed or deferred if the invest igator believes that obtaining t hem might increase subject risk.  
Additionally, a study-related laborator y specimen that is unevaluable due to clotting or laboratory related 
issues will not be repeated.  If a study related labora tory draw is delayed or deferred, study staff will 
document this on a source document. 
h) Ganciclovir concentrations will be obtained with one of  the Study Assessment Dose s 3, 4, 5, 6, 7, or 8 
(Window: Study Assessment Day 1 through Study Assess ment Day 5) at the following time points:  0h 
(immediately prior to IV ganciclovir dose; window: -15 min), 1h (immediately after the end of the IV 
ganciclovir dose; window: +15 min), 2-3h, 5-7h, and 10 -12h; required amount of whole blood for plasma 
ganciclovir determination at each time point is 200 L (0.2 mL).  Study related laboratory draws will be 
delayed or deferred if the investigator believes that obtaining them might increase subject risk.  Additionally, 
a study-related laboratory specimen that  is unevaluable due to clotting or laboratory related issues will not 
be repeated.  If a study related laboratory draw is delayed or deferred, study staff will document this on a 
source document. 
i) If desired by [CONTACT_172276], ganciclovir conc entrations may be obtained around one dose during the 
window at the following time points:  0h (immediatel y prior to IV ganciclovir dose; window: -15 min), 1h 
(immediately after the end of the IV ganciclovir dose; window: +15 min), 2-3h, 5-7h, and 10-12h; required 
amount of whole blood for plasma ganciclovir determination at each time point is 200 L (0.2 mL).  Optional 
laboratory draws are not required by [CONTACT_760], and so no documentation on a source document will be 
required. 
j) If subject weighs < 575 grams, the second set of PK draws cannot be performed (would exceed blood draw 
parameters of 7 mL/kg over 42 days) 
k) To be obtained only once per study period; ideally, at least 72 hours should separate viral loads being 
obtained in different study periods 
l) Required amount of whole blood for CMV PCR is 0.[ADDRESS_554038] risk.  Additionally, a study-
related laboratory specimen that is unevaluable due to  clotting or laboratory related issues will not be 
repeated.  If a study related laboratory draw is delay ed or deferred, study staff will document this on a 
source document. 
m) If subject weighs < 600 grams, the virology specimen for CMV viral load will not be performed (would exceed 
blood draw parameters of 7 mL/kg over 42 days) 
n) If subject weighs < 650 grams, the virology specim en for CMV viral load will not be performed (would exceed 
blood draw parameters of 7 mL/kg over 42 days) 
o) Urine collection will be non-invasive (e.g., bagged, in dwelling foley catheter, excess clinical specimen, etc.).  
If urine is obtainable, it will be frozen and sent to the UAB Central Laboratory for processing. If an attempt to 
Collaborative Antiviral Study Group                                                     DMID Protocol #11-0067, Version 2.[ADDRESS_554039] 2015 
 
  
 _____________________________________________________________________________________________  
52 obtain urine for CMV detection is unsuccessful, stud y staff will document the failed attempt on a source 
document. 
p) mg/dose, dosing interval, subject weight  
q) Once during each Study Period the study team will re cord the number of PRBC transfusions received by [CONTACT_437251] (for the Period 1 documentation) or since the last recording (for 
documentation for Periods 2-7).  A PRBC transfusion is defined as ≥ 10 mL/kg of PRBCs within a 24 hour 
period. 
 
 
  
 